Treatments with therapeutic phlebotomy and hydroxyurea are associated with improved overall survival and decreased risk of thrombosis in older patients with polycythemia vera, according to a recent ...

A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...

Takeda & Protagonist submit NDA to US FDA seeking approval for rusfertide to treat polycythemia vera: Osaka, Japan Wednesday, January 7, 2026, 17:00 Hrs [IST] Takeda, focused on c ...

Of the 18 PV patients treated with PTG-300, the vast majority were able to eliminate therapeutic phlebotomies and maintain a target hematocrit level of less than 45 percent. Treatment with PTG-300 was ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced details from a poster presentation with final data from the rusfertide Phase 2 REVIVE study. Rusfertide, a mimetic of the ...

Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with ...

CHARLESTON, S.C.--(BUSINESS WIRE)--The Blood Connection (TBC), your community blood center, is proud to serve the Charleston community through free therapeutic phlebotomy. This service is free for ...

NEWARK, Calif., Dec. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating ...

PARKVILLE, Mo.--(BUSINESS WIRE)--Bond Biosciences, Inc. “We are pleased to begin this first-in-human clinical trial of our lead non-absorbed oral therapy and thankful for the seasoned development team ...

Robin Meyer was adamant: “We have to do something for this patient.” Meyer, R.N.C. infusion nurse at AHN Cancer Institute at Saint Vincent, identified an urgent and important need for her patient, ...